Alliancebernstein L.P. Verastem, Inc. Transaction History

Alliancebernstein L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.02 - $1.83 $116,382 - $208,803	-114,100 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$1.06 - $2.1 $424 - $840	400 Added 0.35%	114,100 $161,000
Q4 2021 Feb 14, 2022	BUY	$2.05 - $3.2 $34,440 - $53,760	16,800 Added 17.34%	113,700 $233,000
Q2 2021 Jul 30, 2021	BUY	$2.57 - $4.85 $167,564 - $316,220	65,200 Added 205.68%	96,900 $394,000
Q1 2021 May 06, 2021	SELL	$1.9 - $2.82 $61,750 - $91,650	-32,500 Reduced 50.62%	31,700 $78,000
Q3 2020 Nov 12, 2020	SELL	$1.11 - $1.68 $203,130 - $307,440	-183,000 Reduced 74.03%	64,200 $78,000
Q2 2020 Aug 13, 2020	BUY	$1.69 - $4.2 $417,768 - $1.04 Million	247,200 New	247,200 $425,000
Q2 2019 Aug 14, 2019	SELL	$1.25 - $3.14 $141,875 - $356,390	-113,500 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$2.79 - $4.09 $72,261 - $105,931	25,900 Added 29.57%	113,500 $336,000
Q2 2018 Aug 13, 2018	BUY	$2.88 - $8.67 $252,288 - $759,492	87,600 New	87,600 $603,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.17B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.